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ABSTRACT:  49 
Delivery of drugs and biomolecules into skin has significant advantages. To achieve this, 50 
herein, we report a nanomaterial strengthened dissolving microneedle patch for transdermal 51 
delivery. The patch comprises thousands of microneedles which are composed of dissolving 52 
polymers, nanomaterials and drug/biomolecules in their interior. With the addition of 53 
nanomaterials, the mechanical property of generally weak dissolving polymers can be 54 
dramatically improved without sacrificing dissolution rate within skin. In our experiments, as 55 
a test case, we incorporated layered double hydroxides (LDH) nanoparticles into sodium 56 
carboxymethylcellulose (CMC) to form a nanocomposite. The results show that, by adding 5 57 
wt% of LDH nanoparticles into CMC, the elastic modulus of the polymer increases from 58 
0.993±0.065 GPa to 2.878±0.123 GPa, which is comparable to that of engineering plastics 59 
(e.g., 2.0-2.6 GPa for polycarbonate). Small and densely packed CMC-LDH microneedles 60 
penetrate human and pig skin more reliably than pure CMC ones and attractively the 61 
nanocomposite strengthened microneedles dissolve in skin and release payload within only 1 62 
minute. Finally, we tested the application of using our nanocomposite strengthened 63 
microneedle arrays for in vivo vaccine delivery and the results showed that significantly 64 
stronger antibody response could be induced when compared with that generated by 65 
subcutaneous injection. These data suggest that nanomaterials could be useful for fabricating 66 
densely packed and small polymer microneedles that have robust mechanical properties and 67 
rapid dissolution rate and therefore potential use in clinical applications. 68 
1. Introduction 69 
Microneedles are tiny projections of micrometer dimensions and have the capability of 70 
delivering drugs and biomolecules to skin.[1-5] This transdermal delivery platform has many 71 
advantages over conventional subcutaneous and intramuscular injection by needle and 72 
syringe. First, there is no or minimal pain, cross-infection and needle stick injuries.[6-8] 73 
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Second, microneedle can be designed to target specific layer of skin. Third, there is potential 74 
for self-administration. Last but not least, it can be used when there is a significant first-pass 75 
effect of the liver that can prematurely metabolize drugs.[9] Microneedle arrays are usually 76 
made of silicon, metals and polymers.[10] Among them, polymer microneedle arrays are 77 
increasingly attractive because they are expected to be less expensive to mass produce than 78 
silicon or metal arrays and safer during application. Drugs and biomolecules can be 79 
incorporated into the interior of microneedles themselves when using dissolving 80 
polymers.[8,11] During application, the polymer structure rapidly dissolves in skin, thereby 81 
releasing the drug and biomolecules, so there is no sharp waste.  82 
Despite their promising features, dissolvable polymers generally have very weak 83 
mechanical properties. The need for combination of biocompatibility, robust mechanical 84 
properties and rapid dissolution rate severely limits the choice of polymer. 85 
Polyvinylpyrrolidone (PVP)[1,8,11] and carboxymethylcellulose sodium salt (CMC)[7,12] are 86 
commonly reported for making dissolving polymer microneedles. For example, PVP 87 
microneedles were fabricated by either in-situ polymerization of monomers under UV 88 
conditions (using a 100 W UV lamp) or heating at 80 C for 24 hours.[1,8,11] These harsh 89 
conditions may seriously limit the incorporation of drug and biomolecules that are 90 
temperature or UV sensitive. On the other hand, CMC microneedles can be fabricated at room 91 
temperature, but CMC has weak mechanical properties. For example, the elastic modulus of 92 
CMC is only around 1 GPa.[12] It is expected that the bioresorbable polymer microneedle size 93 
needs to be relatively large to reliably pierce human skin.[12]  This would apparently constrain 94 
the density of microneedles on an array. However, recent study shows that small (base 95 
diameter or width < 40 µm) and densely packed microneedles (over 10,000 microneedles per 96 
cm2) may lead to significantly enhanced vaccine efficacy when compared to large and 97 
sparsely packed ones.[13,14] In addition, small microneedles can be easily dried during 98 
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fabrication and dissolve rapidly in skin during application. Therefore, improving the 99 
mechanical properties of dissolving polymer microneedles could be beneficial in terms of 100 
drug efficacy and design flexibility as well as ease in fabrication and rapid dissolution in the 101 
skin.  102 
To achieve this, we hypothesize that the use of reinforcing nanofillers will result in an 103 
advanced biomedical material that can make enhanced dissolving polymer microneedles that 104 
are mechanically more robust, while retaining the capacity to rapidly dissolve. Layered 105 
double hydroxide (LDH) nanoparticles have been commonly used to reinforce a variety of 106 
polymers.[15] For example, by adding only 1 wt% of LDH nanoparticles into nylon 6, the 107 
elastic modulus of the composite increases 100% in comparison with that of pure nylon 6 108 
polymer.[16] Therefore, in this paper, we have examined the potential for LDH nanoparticles 109 
to enhance the mechanical strength of CMC cast in microneedle arrays for potential drug and 110 
biomolecule delivery. We are the first to report the use of nanomaterials to improve the 111 
mechanical characteristics of dissolving microneedle arrays for transdermal delivery. 112 
2. Results 113 
2.1. Characterization of Mg2Al-Cl-LDH Nanoparticles  114 
We firstly prepared Mg2Al-Cl-LDH nanoparticles with a mean size of 80 nm and zeta 115 
potential of +40 mV in aqueous and buffer-free solution (Figure 1a-c). The as-prepared 116 
aqueous suspension contained well suspended LDH nanoparticle without aggregation (Figure 117 
1a-b).  XRD pattern shows the typical feature of Mg2Al-Cl-LDH nanoparticles (Figure 1d). 118 
Diffraction peaks shown in the XRD pattern of pristine LDH nanoparticles correspond to the 119 
(003), (006) and (009) plane reflections of LDH. 120 
2.2. Mechanical Properties of CMC and CMC-LDH Nanocomposite 121 
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We incorporated varying amounts of LDH into 2 wt% CMC aqueous solution to test the 122 
strengthening effect of LDH nanoparticles on the mechanical properties of CMC. After the 123 
samples were dried, nanoindentation was used to measure their elastic modulus and hardness. 124 
Figure 2a shows typical load–displacement curves of CMC polymer with different 125 
concentrations of LDH nanoparticles. The nanoindentation cycle consists of three periods: 126 
loading-holding-unloading. Loading forces were increased at constant velocity and the 127 
nanoindenter tip sank into materials during the loading period, which contributed to both 128 
elastic and plastic deformation. Strong materials require a high force to achieve the same 129 
penetration depth during the loading period.[16]  As we can observe from Figure 2a, much 130 
greater load is required for penetration of the same depth as LDH nanoparticle concentration 131 
increases from 0 wt% to 2, 5 and 10 wt% (relative to the mass of CMC in the samples). 132 
Apparently, adding LDH nanoparticles into CMC can significantly enhance its resistance to 133 
indentation and make CMC-LDH composite much stronger than pure CMC. Figure 2b and 134 
Figure 2c show the elastic modulus and hardness of polymers, respectively, calculated from 135 
unloading. The elastic modulus of pure CMC is 0.993±0.065 GPa. The elastic modulus of 2 136 
wt% of LDH loaded CMC increased to 1.489±0.036 GPa. With LDH concentration increased 137 
to 5 wt%, the elastic modulus reaches 2.878±0.123 GPa. The elastic modulus increased to 138 
290% of that of pure CMC polymer when 5 wt% of LDH nanoparticles were added to CMC 139 
(p < 0.001). When the LDH concentration was increased to 10 wt%, the elastic modulus of 140 
the nanocomposite started to decrease. It should be noted that the hardness of pure CMC 141 
polymer is 0.067±0.001 GPa. The addition of LDH nanoparticles to CMC increased the 142 
hardness of the composite material to 0.080±0.001 GPa, 0.111±0.004 GPa and 0.118±0.001 143 
GPa for CMC composites with 2 wt%, 5 wt% and 10 wt% of LDH nanoparticles, 144 
respectively. 145 
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Based on these results we chose the CMC composite with 5 wt% LDH nanoparticles as 146 
the starting material for preparing microneedle arrays. Since centrifugation (3000 × g for 10 147 
minutes) was used to force the viscous polymer solution to fill in the tiny cavity of a 148 
microneedle PDMS mold, the concentration of CMC aqueous solution was increased to 5 149 
wt% to avoid unequal LDH nanoparticle distribution within the centrifuged microneedles. 150 
When 5 wt% LDH (relative to the mass of CMC) was added to the 5wt% CMC solution 151 
followed by centrifugation at 4000 × g for 10 minutes, negligible amount of LDH 152 
nanoparticles was sedimented by simply observing the mixture solution. The bottom layer of 153 
the solution was discarded and supernatant was used for nanoindentation measurements. The 154 
results show that the elastic modulus of 5 wt% CMC/5 wt% LDH was 2.486±0.186 GPa. The 155 
value is slightly lower than the highest elastic modulus of the sample dried from the solution 156 
of 2 wt% CMC incorporating with 5 wt% LDH, but it is still much better than that of pure 157 
CMC (p < 0.001). The suspension of 5 wt% CMC/5 wt% LDH was then used for fabricating 158 
microneedles. 159 
2.3 Characterization of CMC-LDH Nanocomposite Microneedle Patches  160 
The validation of the hypothesis that incorporation of LDH nanoparticles into CMC 161 
could significantly increase the mechanical properties of the polymer supported the use of this 162 
nanofiller-improved polymer to fabricate and test microneedle arrays. Figure 3a and Figure 163 
3b are representative SEM images of silicon microneedle male molds used to prepare PDMS 164 
female molds for polymer microneedle fabrication. The height and density of silicon 165 
microneedles are 218 µm and 11,900 projections cm-2, respectively. Figure 3c and Figure 3d 166 
show typical SEM images of our dissolving polymer microneedles. The polymer 167 
microneedles had uniform morphology and geometry. The microneedles were pyramidal in 168 
shape and the tip radius is below 500 nm. The length of these fabricated polymer projections 169 
is 165±3 µm (n=20 projections). This indicates a 24±1% reduction in length in comparison 170 
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with that of the microneedles of the male mold. This decrease is mainly due to the contraction 171 
and solidification of CMC based composite materials during drying. 172 
2.4. Confocal Microscopy Study of the Penetration and Payload Delivery of 173 
Nanocomposite Microneedle Patches in Human and Pig Skin 174 
Once nanocomposite microneedle patches were successfully made, the next key 175 
question was whether these microneedles can reliably penetrate stratum corneum and delivery 176 
payload to skin? To perform this study, FITC-Dextran was simply mixed with CMC-LDH 177 
nanoparticle solution as a viewable drug and biomolecule surrogate and then cast onto the tips 178 
of microneedles and then we tested nanofiller composite microneedle penetration in excised 179 
pig and human skin. To determine whether the microneedles can uniformly penetrate skin, 180 
reflectance confocal microscopy (RCM) was used to image both the treated pig skin and 181 
human skin (representative images shown in Figure 4a-d). Nanocomposite microneedles 182 
applied to pig skin resulted in successful breaching of the stratum corneum and uniform 183 
penetration within the skin across the array (Figure 4a). The penetration depth analyzed from 184 
the RCM images was 71±7 µm (n = 40 projections). These results differed from what was 185 
observed for the CMC only microneedles where the penetration was not uniform (Figure 4b). 186 
The center area shows penetration but no penetration holes are able to be clearly observed in 187 
the rest area. The depth of the penetration in the center area was found to be 46±12 µm (n = 188 
40 projections, p < 0.001 between CMC and CMC-LDH microneedles penetration in pig 189 
skin). The nanocomposite microneedles also resulted in successful breaching and penetration 190 
into human skin (Figure 4c) with a depth of 64±9 µm (n = 40 projections). The CMC only 191 
microneedles resulted in indents on the skin surface with minimal penetration of 39±8 µm (n 192 
= 40 projections, p < 0.001 between CMC and CMC-LDH microneedle penetration in human 193 
skin) (Figure 4d). Besides achieving apparent deeper penetration depth in both pig and human 194 
skin, CMC-LDH nanocomposite microneedles can be more reliable on successful application 195 
Submitted to  
 
 - 8 - 
while CMC microneedles result in inconsistent penetration across the array, due to the 196 
microneedles bending on skin surface sometimes.  197 
The RCM samples were then imaged using laser scanning confocal microscopy 198 
(LSCM) to determine payload dissolution and diffusion within the skin (representative images 199 
shown in Figure 5a-h). For pure CMC microneedle applied skin samples, the images were 200 
selected from the area where penetration of microneedles into skin was achieved. The 201 
delivery sites are clearly observed from the top view of the skin samples (Figure 5a, 5c, 5e 202 
and 5g), which further confirms the polymer microneedles are able to pierce stratum corneum. 203 
For some delivery sites, it is obvious to see the holes created by the microneedle penetration. 204 
The corresponding 3-D images (Figure 5b, 5d, 5f and 5h) clearly show that the FITC payload 205 
was delivered vertically to certain depths beneath the skin surface. In a number of delivery 206 
sites, it is even possible to see that the delivery payload started to diffuse a lot within the skin 207 
after only 5 minutes. Collectively, Figure 5 demonstrates that the microneedles were capable 208 
of piercing stratum corneum followed by dissolving in the skin and delivering the FITC 209 
payload to the thin layer beneath the skin surface. 210 
Now we have confirmed that the CMC-LDH nanocomposite microneedles can reliably 211 
penetrate skin and deliver the payload into skin. Compared with CMC microneedles, the 212 
nanomaterial strengthened microneedles result in more consistent penetration within the skin 213 
cross the whole patch area. Another key question is whether these mechanically strengthened 214 
microneedles can still rapidly dissolve in skin? To investigate this, we observed the 215 
microneedles before application in skin and at 1, 2 and 5 minutes after skin penetration. The 216 
results are shown in Figure 6. The figure shows the merged fluorescence and reflectance 217 
confocal microscopy images of microneedles before and after being applied to skin. Before 218 
application, the fluorescent payload can be clearly seen in green throughout the shaft of the 219 
microneedles (Figure 6a). No fluorescence signal could be detected at the base of the array, 220 
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which has the added benefit of reducing cost through conserving drug molecules to the 221 
microneedles only and therefore reducing drug wastage during delivery. Because of this, in 222 
our experiments, minimal fluorescence was seen on the surface between the microneedles due 223 
to the payload being cast within the projections instead of ‘wasted’ in the backing layer of the 224 
microneedles. After skin application, it can be seen that almost all of the microneedles are 225 
dissolved in the skin after only 1 minute. 226 
2.5. In vivo Delivery of Antigen to Skin and Successful Immunization of Mice 227 
Having confirmed that our nanocomposite microneedles can robustly penetrate, quickly 228 
deliver payload to human and pig skin and target specific skin layers, next we test the 229 
application of the nanocomposite microneedle arrays for vaccine delivery. We fabricated 230 
CMC and CMC-LDH microneedle arrays with 10 and 1.65 µg of ovalbumin (OVA) protein, 231 
respectively. Pure CMC polymer microneedle arrays were used as a control in the experiment. 232 
Mice were anesthetized and a single microneedle patch was applied to each ear, therefore 2 233 
microneedle patches were used for each mouse. As a positive control, we subcutaneously 234 
injected 20µg of OVA protein to mice. The induced antibody titers of mice are shown in 235 
Figure 7. From the figure, the following can be observed. At 14 days after primary 236 
immunization, subcutaneous (SC) injection of 20 µg of OVA protein induced negligible 237 
immune response compared with that of unimmunized mice. In great contrast, both CMC and 238 
CMC-LDH microneedle vaccination led to great immune response indicated by the high 239 
antibody titer shown in Figure 7a. The antibody titers between the two microneedle 240 
immunized groups do not show statistical difference (p > 0.1). If we compare the standard 241 
error of the mean of the two microneedle groups, it is easy to find that the antibody titers 242 
generated by CMC-LDH microneedle patch vaccination are more consistent than those 243 
induced by CMC microneedle immunization. 244 
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The mice were then boosted at 17 days after primary immunization and sera were 245 
collected at 21 days after the boost (38 days after primary vaccination). From Figure 7b, it can 246 
be seen that, after boost, SC injection of 20 µg of OVA protein led to reasonably high 247 
antibody titers, although still much lower than those induced by microneedle vaccination (p < 248 
0.001). The other finding is that, after boost, CMC-LDH microneedle arrays containing 3.3 µg 249 
of OVA protein led to stronger immune response than that induced by pure CMC microneedle 250 
patches with 20 µg of OVA protein (p < 0.001).  251 
 3. Discussion 252 
In this paper, we hypothesized that the LDH nanoparticles could enhance the 253 
mechanical properties of CMC microneedles and thereby improve transdermal delivery. We 254 
chose CMC because it had often been used as a material in dissolving microneedles[7,12] in the 255 
literature, but the elastic modulus of CMC is only 1 GPa[12], which potentially limits the 256 
successful application of CMC microneedles in transdermal drug and biomolecule delivery 257 
for humans, particularly when one needs to fabricate densely packed microneedles for certain 258 
needs. LDH nanoparticles were selected to increase the mechanical strength of CMC because 259 
of their high biocompatibility, high aspect ratio (lateral size over thickness), low cost and 260 
previous use in enhancing mechanical strength in polymers.[15-17] Furthermore, CMC is 261 
negatively charged in solution and may well be incorporated into the internal layers of LDH 262 
nanoparticles and help disperse LDH nanoparticles uniformly. Consistent dispersion is a 263 
crucial challenge when formulating nanofillers to mechanically strengthen polymers as better 264 
dispersion of nanomaterials/fillers leads to enhanced mechanical properties.[15] The 265 
mechanical strength of CMC was greatly enhanced by adding LDH nanoparticles. The elastic 266 
modulus of our CMC-LDH composite microneedles is comparable to that of engineering 267 
plastics, e.g. 2–4 GPa for nylon and 2.0-2.6 GPa for polycarbonate. This improvement has the 268 
capacity to increase the flexibility of drug and molecule formulations that can be incorporated 269 
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into dissolving microneedle arrays. It is expected that the addition of drug and molecules, 270 
composed primarily of proteins and salts, will worsen the mechanical properties of the 271 
structural polymer in a concentration dependent manner. The addition of reinforcing 272 
nanofillers could help to curb that effect such that the final microneedle array remains useful 273 
for animal and human applications. 274 
Our fabrication process was operated at room temperature (23 C). Lowering the 275 
temperature to optimize the stability of the drugs and molecules could be explored using this 276 
casting technique. The entire fabrication process required no heating, UV illumination or any 277 
other harsh conditions or treatments and therefore our technique is suitable for incorporating 278 
delicate drugs and biomolecules into microneedles for subsequent transdermal delivery. The 279 
enhanced mechanical properties of the CMC-LDH composite microneedles successfully 280 
pierced pig and human skin to deliver a FITC-labeled dextran payload. Importantly, the 281 
nanoparticle strengthened polymer microneedles retained the capacity to dissolve quickly, 282 
within only 1 minute. Quick dissolution within skin is crucial for a short administration time. 283 
For comparison, in a previous report, methacrylic acid (MAA) was copolymerized with vinyl 284 
pyrollidone (VP) to form poly(vinylpyrrolidone-co-methacrylic acid) (PVP-MAA) to improve 285 
the mechanical strength of the fabricated microneedles. However, with the addition of MAA, 286 
the dissolution rate of the microneedles greatly slowed. For example, PVP-MAA 287 
microneedles (25% MAA) need 2 hours to dissolve within porcine skin while at the same size 288 
pure PVP microneedles dissolve within 15 minutes.[8]  289 
Skin contains abundant of immune cells and the density of these cells is much high than 290 
that in subcutaneous tissue and muscle to which vaccines are usually delivered by needle and 291 
syringe injection. Therefore, if we can deliver vaccines to the skin layers, their efficacy should 292 
be greatly enhanced. Although it is possible to use conventional needle and syringe to achieve 293 
intradermal injection for delivering vaccine to the skin, it is technically challenge to perform 294 
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because the skin is very thin. To achieve reliable skin delivery, many approaches such as 295 
liquid jet injection, biolistic microparticle injection, thermal or laser assisted delivery and 296 
microneedles have been developed. [18] When these approaches were tested for vaccine 297 
delivery to skin and compared with conventional intramuscular (IM) or SC injection, it was 298 
found that the vaccine efficacy was dramatically improved. [19-22] To test whether our 299 
nanocomposite strengthened microneedle arrays can pierce skin and deliver payload to the 300 
targeted skin layers, we investigated the penetration and payload delivery by RCM and 301 
LSCM. The results confirmed that the composite microneedles successfully penetrated 302 
stratum corneum and delivered the FITC-labeled dextran payload up to around 64±9 µm 303 
below the human skin surface. The human epidermis layer contains high density of APCs and 304 
its thickness, using human forearm dorsal epidermis as an example, is 61.3±11.0 m.[23] This 305 
means that most of the payload was delivered within the target layer.  306 
Once demonstrating that the nanocomposite strengthened microneedle arrays could 307 
deliver payload to skin, next key question will be whether they can induce robust immune 308 
response. To investigate this, we loaded OVA protein in the microneedle arrays and 309 
performed immunization trial in mouse model. The results suggested that dissolvable pure 310 
CMC microneedle patches could induce much stronger immune response when compared 311 
with conventional efficient SC injection (generally more efficient than the commonly used 312 
intramuscular injection). Attractively, it was confirmed that the nanocomposite strengthened 313 
microneedle arrays worked even better than the pure dissolvable ones. This is in line with the 314 
findings from the penetration experiments. Because nanocomposite strengthened microneedle 315 
arrays could penetrate skin better and worked more reliably, it was apparent that the 316 
strengthened arrays should deliver more vaccine dose into skin. In other words, 317 
nanocomposite strengthened microneedle arrays were capable of increasing vaccine delivery 318 
efficiency.  319 
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Moreover, LDH nanoparticles have been widely used for efficient delivery of a range of 320 
drugs such as anticancer drug methotrexate (MTX),[24,25] low molecular weight heparin 321 
(LMWH),[26] siRNA[27-29] and plasmid DNA.[30,31] The biocompatibility and safety profiles 322 
obtained these studies will certainly help the potential use of LDH nanoparticles in our 323 
nanocomposite microneedle arrays in future clinical applications. In the meantime, it also 324 
opens the opportunity of incorporating vaccine into LDH nanoparticles for transdermal 325 
nanovaccine delivery. This will be very suitable for DNA and siRNA delivery because these 326 
molecules need to enter cells to be functional and their existence in nanovaccine form will 327 
greatly increase their intracellular delivery. In this case, LDH nanoparticles will play 328 
multifunctional roles including mechanical strengthening and nanovaccine carrier. 329 
4. Conclusion 330 
In this study, we demonstrated that LDH nanoparticles can reinforce dissolving polymer 331 
microneedles. By adding 5 wt% of LDH into CMC, the elastic modulus increases from 332 
0.993±0.065 GPa to a maximum of 2.878±0.123 GPa (p < 0.001). Additionally, we 333 
successfully manufactured LDH nanoparticle-reinforced, dissolving polymer microneedles 334 
with uniform shape and size. The polymer microneedles have an extremely sharp tip with an 335 
average radius below 500 nm. The fabrication process was conducted at room temperature 336 
without the need for any harsh conditions that may degrade drugs and biomolecules. Confocal 337 
microscopy results confirmed that the nanofiller strengthened the dissolving microneedles by 338 
improving their mechanical properties to allow the microneedles to reliably pierce into pig 339 
and human skin, while pure CMC polymer microneedle were more likely to bend on the 340 
surface of skin. The composite microneedles retained the capacity to dissolve rapidly in skin 341 
within only 1 minute and released the incorporated payload. The payload distribution was 342 
highly localized within the skin. Finally, we tested the application of using our nanocomposite 343 
strengthened microneedle arrays for vaccine delivery and the results showed that significantly 344 
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stronger antibody response could be induced when compared with subcutaneous injection. 345 
Overall, this represents an important step toward dissolving microneedles that have robust 346 
mechanical properties with potential use in clinical applications. 347 
4. Experimental Section 348 
Preparation of Mg2Al-LDH Nanoparticles: Mg2Al-LDH nanoparticles were prepared 349 
according to the method described by Xu et al.[32,33] Briefly, 40 ml of 0.15 M NaOH 350 
(International Laboratory, USA) solution was mixed with 10 ml of solution containing 2.0 351 
mmol of MgCl2 (International Laboratory, USA) and 1.0 mmol of AlCl3 (International 352 
Laboratory, USA) under vigorous stirring. The container was sealed and the solution was 353 
under stirring for 10 minutes. Next, the solution was centrifuged and washed once with water. 354 
The obtained slurry was dispersed in 40 ml of water and hydrothermally treated at 80 ℃ for 4 355 
hours in an airtight container. The concentration of LDH is about 0.4 wt%. The mass of LDH 356 
was determined by weighing the LDH mass collected from suspension. 357 
Fabrication of CMC-LDH Nanocomposites: LDH solutions with different concentrations 358 
were mixed with CMC (Mw 90,000, Sigma-Aldrich, USA) to make composite solution. 359 
Briefly, 10 ml of LDH solutions with different concentrations were mixed with 200 mg of 360 
CMC to prepare composite solution followed by placing in fume hood and drying to obtain 361 
polymer nanocomposite. The prepared nanocomposites contained 2 wt%, 5 wt% and 10 wt% 362 
LDH nanoparticles. The weight percentage is the mass ratio of LDH nanoparticles to CMC. 363 
During microneedle fabrication, CMC-LDH solution was centrifuged onto the mold at a 364 
speed of 3000 × g for 10 minutes. To mimic this process, for another batch of samples, 10 ml 365 
of solution containing 25mg LDH nanoparticles was mixed with 500 mg of CMC and the 366 
mixture was sonicated for 30 minutes. After that, the solution was centrifuged for 10 min at 367 
4000 × g. The amount of the nanoparticles which were centrifuged to the bottom of solution 368 
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was trivial. The upper layer of solution was collected and sonicated for 30 minutes for being 369 
used to make nanoindentation samples and microneedle arrays.  370 
Fabrication of Dissolving Polymer Microneedle Patches: Silicon microneedle arrays 371 
were used as male mold. The arrays were fabricated according to methods described in 372 
literature.[34] Briefly, a slicon wafer was diced by a diamond blade to create silicon 373 
microcolumns of required dimension and spacing. A two-step isotropic etching using a 374 
mixture of nitric acid and hydrofluoric acid was used to fabricate sharp microneedles. This 375 
silicon microneedle array male mold was washed with ethanol for 3 times and dried in air and 376 
then PDMS was slowly poured over the surface of silicon microneedle array. The silicon 377 
microneedle array male mold immersed in PDMS was placed in a fume hood for curing for 24 378 
hours. After curing, the silicon microneedle array male mold was peeled off and the PDMS 379 
female mold was washed with water and ethanol for 3 times before casting. Figure 8 shows 380 
the steps to manufacture a dissolving polymer microneedle patch. Figure 8-1 shows the 381 
PDMS mold. To make microneedle patches, firstly, 30 µl of LDH-CMC composite solution 382 
was added to the surface of mold (Figure 8-2). Then the mold was sealed (Figure 8-3) and 383 
centrifuged at 3000 × g for 10 minutes. After centrifugation, the solution remaining on the 384 
surface of the mold was collected by pipette and the mold was placed in a fume hood to dry 385 
for 30 minutes. During the drying period, a solid microneedle tip was fabricated (Figure 8-5). 386 
Subsequently, 40 µl of LDH-CMC composite solution was added to the surface (Figure 8-6) 387 
and the mold was sealed (Figure 8-7) and centrifuged for 10 minutes. Finally, 200 µl of LDH-388 
CMC composite solution was added to the surface of centrifuged mold and placed in a fume 389 
hood for drying. After 8 hours, the mold was placed in a sealed desiccator. When the 390 
microneedle patch was dried completely, it was removed from the mold (Figure 8-9) and 391 
stored in a dessicator until use. 392 
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Characterization: Nanoindentation was carried by a MTS Nano Indenter XP® (MTS 393 
Cooperation, Nano Instrument Innovation Center, NT) with three-sided pyramid (Berkovich) 394 
diamond indenter. The indenter was pressed into materials with constant strain rate (0.05 1/s) 395 
from the sample surface into 2000 nm deep. The fabricated polymer microneedle patch was 396 
observed by scanning electron microscope (JEOL JSM-820 and FEG-SEM JEOL JSM-6335 397 
F). The samples were tilted 45 for SEM. 398 
Microneedle Application to Excised Skin: Excised pig ears were obtained from the local 399 
abattoir (Highchester Pty Ltd, Gleneagle, Australia). The ventral side of the ear was lightly 400 
shaved followed by thoroughly rinsing. The ventral skin (epidermis and dermis) was then 401 
separated from the ear (cartilage) using tweezers and scalpel. Excised human skin was 402 
obtained from abdominal plastic surgery patients. On arrival the adipose tissue was removed 403 
using a scalpel and the skin was rinsed. All patients signed an informed consent approved by 404 
the Princess Alexandra Hospital Research Committee approval no. 097/090. Skin (both pig 405 
and human) was stored at -20 oC prior to use. For microneedle application, the skin (pig or 406 
human) was thawed, rinsed, dried then pinned down taut on a covered corkboard. The tissue 407 
was stored on saline moistened gauze throughout the experiment when not in use.  A 408 
microneedle array was then applied using a spring applicator for 1, 2 or 5 minutes (n = 3 per 409 
skin type). After microneedle application, the treatment area was excised with an 8 mm 410 
biopsy and the tissue fixed in 1 mL 4% formaldehyde in methanol for 1 hour. Following 411 
fixing, the tissue was removed and washed 3 times for 10 minutes in 1 mL 0.1M phosphate 412 
buffered saline. The samples were then stored at 4 oC until imaging. 413 
Confocal Microscopy Observation of Skin after Patch Application: Reflectance confocal 414 
microscopy was done using a Vivascope® 1500 Multilaser (Lucid Inc., Rochester, NY, 415 
U.S.A). The protocol was adapted from a previously published procedure.[35] Briefly, a laser 416 
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diode was used to excite the tissue at 830 nm. ImageJ (NIH, U.S.A) was used to analyse the 417 
images. Laser scanning confocal microscopy was done using a Zeiss LSM 510 Meta (Carl 418 
Zeiss Inc., Germany). Prior to imaging the tissue was stained with Hoechst 33342, a nuclei 419 
stain. A stock solution of 10 mg/mL Hoechst 33342 in dimethyl sulfoxide was prepared. A 420 
working solution was made by a 1:1000 dilution in 0.1 M phosphate buffered saline. The 421 
tissue was incubated with the stain for 1 hour at room temperature followed by three washing 422 
steps for 10 minutes in 0.1 M phosphate buffered saline. The wavelengths used to excite the 423 
FITC-dextran and Hoechst 33342 was 488 nm and 405 nm, respectively. 424 
Vaccination of OVA protein vaccine: Three groups of C57BL/6 female mice were 425 
vaccinated with OVA protein either by SC injection using needle and syringe (5 mice in the 426 
group), or microneedle array application (4 mice per group). Another group of four untreated 427 
mice were used as negative control. For SC injection, saline solution with 20 µg OVA protein 428 
was injected to each mouse. For microneedle array vaccination, one patch was applied to one 429 
ear of a mouse (total 2 patches for each mouse). The patches were applied to mice skin by a 430 
spring applicator and kept in place for 2 minutes. At 14 days after primary immunization, sera 431 
were collected. A boost vaccination was given at 17 days post primary vaccination and sera 432 
were collected at 21 days after the boost. 433 
ELISA protocol: ELISA was performed as previously described. [36] Brieﬂy, ELISA plates 434 
(Corning) were coated with 50 µg mL-1 of ovalbumin (Acros) in 0.1M of sodium bicarbonate 435 
buffer (Sigma) overnight at 4oC. These coated plates were used to measure the titers of 436 
speciﬁc IgG induced. Color development was carried out using ABTS (diammonium 2,2-437 
azino-bis(3-ethylbenzothiazoline-6-sulfonate; Sigma) as the substrate. The absorbance 438 
readings at 405 nm were then measured against control wells containing no antiserum in the 439 
reaction. 440 
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 516 
Figure 1. a) HRTEM image of well dispersed Mg2Al-Cl-LDH nanoparticles. b) Particle size 517 
distribution of Mg2Al-LDH suspension. c) The zeta potential of the Mg2Al-LDH nanoparticles in 518 
aqueous and buffer-free solution. d) X-ray diffraction pattern of pristine LDH nanoparticles.  519 
 520 
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 521 
Figure 2. a) Load-displacement curves from nanoindentation. b) Elastic modulus and c) 522 
Hardness of CMC polymer films with different LDH concentrations: A-0 wt%; B-2 wt%; C-5 523 
wt%; D-10 wt% and E-5 wt% with centrifugation. 524 
 525 
 526 
Figure 3. Scanning electron microscopy images of microneedles: a-b) Silicon microneedles 527 
array male mold (inset: digital camera image of a silicon microneedle array); c-d) Fabricated 528 
dissolving polymer microneedles (inset: digital camera image of a polymer microneedle 529 
array). 530 
 531 
 532 
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 533 
 534 
Figure 4. Reflectance confocal microscopy images of skin after 5 minutes microneedle 535 
application: a) pig skin after CMC-LDH nanocomposite microneedle application, b) pig skin 536 
after CMC microneedle application, c) human skin after CMC-LDH nanocomposite 537 
microneedle application, and d) human skin after CMC microneedle application. 538 
 539 
 540 
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 541 
 542 
Figure 5. Laser scanning confocal microscopy images of skin after 5 minutes microneedle 543 
application: a) and b) pig skin after CMC-LDH nanocomposite microneedle application, c) 544 
and d) pig skin after CMC microneedle application, e) and f) human skin after CMC-LDH 545 
nanocomposite microneedle application, and g) and h) human skin after CMC microneedle 546 
application. 547 
 548 
 549 
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 550 
 551 
Figure 6. Merged fluorescence and reflectance confocal microscopy images of CMC-LDH 552 
nanocomposite microneedles: a) before application, b) 1 minute, c) 2 minutes and d) 5 553 
minutes after application to pig skin. 554 
 555 
Figure 7. Total ovalbumin lgG levels at 12 and 38 days post vaccination. Five mice were 556 
subcutaneouly injected with 20 µg of OVA protein to be the positive control. Four 557 
unimmunized mice were negative control. For microneedle immunization, either pure CMC 558 
or CMC-LDH nanocomposite microneedle patches containing different amounts of OVA 559 
protein were used to vaccinate the mice. Each group has four mice. Mice were immunized at 560 
day 0 and boosted at day 17. At day 14 and 38, sera were collected and assayed for antibody 561 
titer measurements. The antibody titers at different dilutions of each group of mice were 562 
shown in the figure. 563 
 564 
 565 
Figure 8. Steps to manufacture a dissolving nanocomposite microneedle patch. 566 
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Highly uniform nanocomposite microneedles array is fabricated under mild conditions. 567 
These very small and densely packed nanocomposite microneedles can mechanically robust 568 
enough to pierce pig/human skin, rapidly dissolve to release payload in targeted layers and 569 
induce robust immune responses. 570 
 571 
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